Labrys Biologics Raises $31M

San Francisco-based Labrys Biologics, a biopharmaceuticals firm focused on treatments for chronic migraine, said this morning that it has raised $31M in a Series A financing round. The round came from venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures. As part of the deal, Labrys said it acquired RN-307, a Phase 2 ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine, from Pfizer. Labrys is headed by Steven P. James. More information »